DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2015-D-2537]

Submission of Quality Metrics Data; Revised Draft Guidance for Industry; Extension of Comment Period

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of availability; extension of comment period.

SUMMARY: The Food and Drug Administration (FDA) is extending the comment period for the notice of revised draft guidance availability that appeared in the Federal Register of November 25, 2016. The Agency is taking this action in response to requests for an extension to allow interested persons additional time to submit comments.

DATES: FDA is extending the comment period on the notice of revised draft guidance availability published on November 25, 2016 (81 FR 85226). Submit either electronic or written comments by March 27, 2017.

ADDRESSES: You may submit comments by any of the following methods:

Electronic Submissions

Submit electronic comments in the following way:

- Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https://www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third
party may not wish to be posted, such as medical information, your or anyone else's
Social Security number, or confidential business information, such as a
manufacturing process. Please note that if you include your name, contact
information, or other information that identifies you in the body of your comments,
that information will be posted on https://www.regulations.gov.

• If you want to submit a comment with confidential information that you do not wish
to be made available to the public, submit the comment as a written/paper submission
and in the manner detailed (see "Written/Paper Submissions" and "Instructions").

Written Submissions

Submit written submissions in the following ways:

• Mail/Hand delivery/Courier (for written/paper submissions): Division of Dockets
  Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
  Rockville, MD  20852.

• For written/paper comments submitted to the Division of Dockets Management, FDA
  will post your comment, as well as any attachments, except for information submitted,
  marked and identified, as confidential, if submitted as detailed in "Instructions."

Instructions: All submissions received must include the Docket No. FDA-2015-D-2537
for "Submission of Quality Metrics Data; Revised Draft Guidance for Industry." Received
comments will be placed in the docket and, except for those submitted as "Confidential
Submissions," publicly viewable at https://www.regulations.gov or at the Division of Dockets
Management between 9 a.m. and 4 p.m., Monday through Friday.

• Confidential Submissions--To submit a comment with confidential information that
  you do not wish to be made publicly available, submit your comments only as a
written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states "THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION." The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on https://www.regulations.gov. Submit both copies to the Division of Dockets Management. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as "confidential." Any information marked as "confidential" will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at:


Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number(s), found in brackets in the heading of this document, into the "Search" box and follow the prompts and/or go to the Division of Dockets Management, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Tara Gooen Bizjak, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, rm. 2109, Silver Spring, MD 20993-0002, 301-796-3257 or Stephen Ripley, Center for Biologics
SUPPLEMENTARY INFORMATION:

In the Federal Register of November 25, 2016, FDA published a notice of revised draft guidance availability with a 60-day comment period. Comments on the notice of revised draft guidance availability will inform FDA's development and proposed implementation of a voluntary phase of the quality metrics program.

FDA is extending the comment period for an additional 60 days, until March 27, 2017. The Agency believes that a 60-day extension of the comment period for the notice of revised draft guidance availability will provide adequate time for interested persons to submit comments without significantly delaying Agency decision making on these important issues.


Leslie Kux,

Associate Commissioner for Policy.

[FR Doc. 2017-00094 Filed: 1/6/2017 8:45 am; Publication Date: 1/9/2017]